These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32259228)

  • 1. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
    Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P
    Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
    Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
    JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
    Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
    Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
    Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD
    Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaratumab for advanced soft tissue sarcoma.
    Tobias A; O'brien MP; Agulnik M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
    Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
    BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
    Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH; Maran A; Robinson SI
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
    Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
    Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.